Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies

Biochimie

Volumn 93, Issue 6, 2011, Pages 1028-1036

  Banu, Hussaina ^a   Renuka, N ^a   Vasanthakumar, Geetha ^a  

^a Manipal University   (United Arab Emirates)

Author keywords

)2 and (; )3; Catalytic activity; CYP2C9 (; Docking simulation; Gliclazide; Molecular dynamics; Natural alleles

Indexed keywords

CYTOCHROME P450 2C9; GLICLAZIDE; HEME; IRON;

ALLELISM; ARTICLE; CATALYSIS; DRUG STABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENOTYPE; HUMAN; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; BIOCATALYSIS; CATALYTIC DOMAIN; ENZYME STABILITY; GENOTYPE; GLICLAZIDE; HEME; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; MOLECULAR DYNAMICS SIMULATION; MUTATION; PHENYLALANINE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 79955062740     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2011.02.008     Document Type: Article

References (61)

1. A. Ward, M. Salas, J.J. Caro, and D. Owens Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime cost of complications in the UK Cost Effect. Resource Allocation 2 2004 2 10
2. J.K. DiStefano, and R.M. Watanabe Pharmacogenetics of anti-diabetes drugs Pharmaceuticals 3 2010 2610 2646
3. K.J. Palmer, and R.N. Brogden Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus Drugs 46 1993 92 125 (Pubitemid 23232408)
4. J. Kirchheiner, I. Roots, M. Goldammer, B. Rosenkranz, and J. Brockmöller Effect of genetic polymorphisms in CYP2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance Clin. Pharmacokinet. 44 2005 1209 1225 (Pubitemid 41832564)
5. J. Kirchheiner, and J. Brockmöller Clinical impact of CYP2C9 polymorphisms Clin. Pharmacol. Ther. 77 2005 1 16
6. A. Holstein, A. Plaschke, M. Ptak, E.H. Egberts, J. El-Din, J. Brockmöller, and J. Kirchheiner Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents Br. J. Clin. Pharmacol. 60 2005 103 106 (Pubitemid 40942788)
7. D.J. Elliot, M.S. Suharjono, B.C. Lewis, E.M. Gillam, D.J. Birkett, A. Gross, and J.O. Miners Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination Br. J. Clin. Pharmacol. 64 4 2007 450 457 (Pubitemid 47404317)
8. J. Blaisdell, L.F. Jorge-Nebert, S. Coulter, S.S. Ferguson, S.J. Lee, B. Chanas, T. Xi, H. Mohrenweiser, B. Ghanayem, and J.A. Goldstein Discovery of new potentially defective alleles of human CYP2C9 Pharmacogenetics 14 2004 527 537 (Pubitemid 39106854)
9. L.J. Dickmann, A.E. Rettie, M.B. Kneller, R.B. Kim, A.J. Wood, C.M. Stei, G.R. Wilkinson, and U.I. Schwarz Identification and functional characterization of a new CYP2C9 variant (CYP2C9 (*)5) expressed among African Americans Mol. Pharmacol. 60 2001 382 387 (Pubitemid 32678304)
10. A.E. Rettie, and J.P. Jones CYP2C9: clinical and toxicological relevance Annu. Rev. Pharmacol. Toxicol. 45 2005 477 494
11. J. Kirchheiner, M. Tsahuridu, W. Jabrane, I. Roots, and J. Brockmöller The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations Future Med. 1 2004 63 84
12. Y.H. Zhou, Q.C. Zheng, Z.S. Li, Y. Zhang, M. Sun, C.C. Sun, D. Si, L. Cai, Y. Guo, and H. Zhou On the human CYP2C9 (*)13 variant activity reduction: a molecular dynamics simulation and docking study Biochimie 88 2006 1457 1465
13. C.R. Lee, J.A. Goldstein, and J.A. Pieper Cytochrome P450 2C9 genetic polymorphisms: a comprehensive review of the in vitro and human data Pharmacogenetics 12 2002 251 263 (Pubitemid 34596790)
14. K. Zhou, L. Donnelly, L. Burch, R. Tavendale, A.S.F. Doney, G. Leese, A.T. Hattersley, M.I. McCarthy, A.D. Morris, C.C. Lang, C.N.A. Palmer, and E.R. Pearson Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study Clin. Pharmacol. Ther. 87 2009 52 56
15. H. Shao, X.M. Ren, N.F. Liu, G.M. Chen, W.L. Li, Z.H. Zhai, and D.W. Wang Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers J. Clin. Pharm. Ther. 35 2010 351 360
16. H. Xu, K.M. Williams, W.S. Liauw, M. Murray, R.O. Day, and A.J. McLachlan Effects of St John's Wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide Br. J. Pharmacol. 153 2008 1579 1586 (Pubitemid 351481511)
17. Y. Zhang, D. Si, X. Chen, N. Lin, Y. Guo, H. Zhou, and D. Zhong Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects Br. J. Clin. Pharmacol. 64 2007 67 74 (Pubitemid 46934414)
18. M.R. Wester, J.K. Yano, G.A. Schoch, C. Yang, K.J. Griffin, C.D. Stout, and E.F. Johnson The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0 resolution J. Biol. Chem. 279 2004 35630 35637 (Pubitemid 39100565)
19. Y. Yao, W.W. Han, Y.H. Zhou, Z.S. Li, Q. Li, X.Y. Chen, and D.F. Zhong The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study Eur. J. Med. Chem. 44 2009 854 861
20. E. Sano, W. Li, H. Yuki, X. Liu, T. Furihata, K. Kobayashi, K. Chiba, S. Neya, and T. Hoshino Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis J. Comput. Chem. 31 2010 2746 2758
21. L.J. Dickman, C.W. Locuson, J.P. Jones, and A.E. Rettie Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9 Mol. Pharmacol. 65 4 2004 842 850 (Pubitemid 38420489)
22. C. Davies, K. Withman, J.R. Scott, A. Pearson, J.J. De Voss, S.E. Graham, and E.M.J. Gillam Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9) Drug Metab. Dispos. 32 2004 431 436 (Pubitemid 38420277)
23. 293 of cytochrome P450 2C9 in substrate recognition and catalytic activity Biochem. J. 370 2003 921 926 (Pubitemid 36399084)
24. C.M. Mosher, M.A. Hummel, T.S. Tracy, and A.E. Rettie Functional analysis of phenylalanine residues in the active site of CYP2C9 Biochemistry 47 2008 11725 11734
25. V. Kumar, J.L. Wahlstrom, D.A. Rock, C.J. Warren, L.A. Gorman, and T.S. Tracy CYP2C9 inhibition: impact of probe selection and pharmaceutics on in vitro inhibition profiles Drug Metab. Dispos. 34 2006 1966 1975 (Pubitemid 44837757)
26. A. Sali, and T.L. Blundell Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 234 1993 779 815 (Pubitemid 24007801)
27. R.A. Laskowski, M.W. MacArthur, D.S. Moss, and J.M. Thornton PROCHECK - a program to check the stereochemical quality of protein structures J. App. Cryst. 26 1993 283 291
28. R.A. Laskowski, R.A. Rullmannn, M.W. MacArthur, R. Kaptein, and J.M. Thornton AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR J. Biomol. NMR 8 1996 477 486 (Pubitemid 126706801)
29. R. Lüthy, J.U. Bowie, and D. Eisenberg Assessment of protein models with three-dimensional profiles Nature 356 1992 83 85
30. J.U. Bowie, R. Lüthy, and D. Eisenberg A method to identify protein sequences that fold into a known three-dimensional structure Science 253 1991 164 170 (Pubitemid 21917131)
31. C.James Phillips, Rosemary Braun, Wei Wang, James Gumbart, Emad Tajkhorshid, Elizabeth Villa, Christophe Chipot, Robert D. Skeel, Laxmikant Kale, and Klaus Schulten Scalable molecular dynamics with NAMD J. Comput. Chem. 26 2005 1781 1802 (Pubitemid 43078511)
32. W. Humphrey, A. Dalke, and K. Schulten VMD - visual molecular dynamics J. Mol. Graph. 14 1996 33 38
33. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera-a visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612
34. D.S. Goodsell, and A.J. Olson Automated docking of substrates to proteins by simulated annealing Proteins 8 1990 195 202 (Pubitemid 20363304)
35. G.M. Morris, D.S. Goodsell, R. Huey, and A.J. Olson Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4 J. Comput. Aided Mol. Des. 10 1996 293 304 (Pubitemid 126712824)
36. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 19 1998 1639 1662 (Pubitemid 128590223)
37. G.D. Szklarz, R.L. Ornstein, and J.R. Halpert Application of 3-dimensional homology modeling of cytochrome P450 2B1 for interpretation of site-directed mutagenesis results J. Biomol. Struct. Dyn. 12 1994 61 78 (Pubitemid 2144559)
38. J. Mestres Structure conservation in cytochromes P450 Proteins 58 2005 596 609 (Pubitemid 40176032)
39. O. Gotoh Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences J. Biol. Chem. 267 1992 83 90
40. L. Afzelius, F. Raubacher, A. Karlen, F.S. Jorgensen, B. Andersson, C.M. Masimirembwa, and I. Zamora Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques Drug Metab. Dispos. 32 2004 1218 1229 (Pubitemid 39410905)
41. J. Kirchheiner, S. Bauer, I. Meineke, W. Rohde, V. Prang, C. Meisel, I. Roots, and J. Brockmöller Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers Pharmacogenetics 12 2002 101 109 (Pubitemid 34298914)
42. T. Oida, K. Yoshida, A. Kagemoto, Y. Sekine, and T. Higashijima The metabolisim of gliclazide in man Xenobiotica 15 1985 87 96
43. A.R. Taylor, R.D. Brownsill, H. Grandon, F. Lefoulon, A. Petit, W. Luijten, P.G. Kopelman, and B. Walther Synthesis of putative metabolism and investigation of the metabolic fate of gliclazide, [1-(3-azabicyclo (3,3,0) oct-3-yl)-3-(4-methylphenylsulfonyl) urea], in diabetic patients Drug Metab. Dispos. 24 1996 55 64
44. M.A. Hummel, P.M. Gannett, J. Aguilar, and T.S. Tracy Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone Arch. Biochem. Biophys. 475 2008 175 183
45. J. Kirchheiner, J. Brockmöller, I. Meineke, S. Bauer, W. Rohde, C. Meisel, and I. Roots Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers Clin. Pharmacol. Ther. 71 2002 286 296 (Pubitemid 34311458)
46. S. Ekins, M.J. de Groot, and J.P. Jones Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites Drug Metab. Dispos. 29 2001 936 944 (Pubitemid 32605906)
47. A. Mancy, P. Broto, S. Dijols, P.M. Dansette, and D. Mansuy The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling Biochemistry 34 1995 10365 10375
48. A. Mancy, S. Dijols, S. Poli, F.P. Guengerich, and D. Mansuy Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding topology Biochemistry 35 1996 16205 16212
49. B.C. Jones, G. Hawksworth, V.A. Horne, A. Newlands, J. Morsman, M.S. Tute, and D.A. Smith Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase) Drug Metab. Dispos. 24 1996 260 266 (Pubitemid 26063913)
50. R.L. Haining, J.P. Jones, K.R. Henne, M.B. Fisher, D.R. Koop, W.F. Trager, and A.E. Rettie Enzymatic determinants of the substrate specificity of CYP2C9: role of B′-C loop residues in providing the π-stacking anchor site for warfarin binding Biochemistry 38 1999 3187 3196
51. A. Melet, N. Assrir, P. Jean, M.P. Lopez-Garcia, C. Marques-Soares, M. Jaouen, P.M. Dansette, M.A. Sari, and D. Mansuy Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid Arch. Biochem. Biophys. 409 2003 80 91 (Pubitemid 36042904)
52. P.A. Williams, J. Cosme, A. Ward, H.C. Angove, D.M. Vinkovic, and H. Jhoti Crystal structure of human cytochrome P450 2C9 with bound warfarin Nature 424 2003 464 468 (Pubitemid 36917499)
53. D. Si, Y. Wang, Y.H. Zhou, Y. Guo, J. Wang, H. Zhou, Z.S. Li, and J.P. Fawcett Mechanism of CYP2C9 inhibition by flavones and flavonols Drug Metab. Dispos. 37 2009 629 634
54. P.H.J. Keizers, B.M.A. Lussenburg, C. de Graaf, L.M. Mentink, N.P.E. Vermeulen, and J.N.M. Commandeur Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic 7-methoxy-4-(aminomethyl)-coumarin metabolism Biochem. Pharmacol. 68 2004 2263 2271 (Pubitemid 39446153)
55. C. De Graaf, C. Oostenbrink, P.H.J. Keizers, M.A.Barbara van Vug-Lussenburg, A.B.Robert van Waterschoot, R.A. Tschirret-Guth, J.N.M. Commandeur, and N.P.E. Vermeulen Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6 Curr. Drug Metab. 8 2007 59 77 (Pubitemid 46043892)
56. M. Ridderstrom, C. Masimirembwa, S. Trump-Kallmeyer, M. Ahlefelt, C. Otter, and T.B. Andersson Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function Biochem. Biophys. Res. Commun. 270 2000 983 987 (Pubitemid 30444818)
57. T.S. Klose, G.C. Ibeanu, B.I. Ghanayem, L.G. Pedersen, L. Li, S.D. Hall, and J.A. Goldstein Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen Arch. Biochem. Biophys. 357 1998 240 248 (Pubitemid 28419205)
58. J.O. Miners, and D.J. Birkett Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br. J. Clin. Pharmacol. 45 1998 525 538 (Pubitemid 28270907)
59. http://www.ic.Nhs.uk/pubs/precostanalysis2005/final/file
60. http://www.medicareaustralia.gov.au/providers/health-statistics/ statistical-reporting/pbs.html
61. http://www.imm.ki.se/CYPalleles/cyp2c9.htm